DOV Pharmaceutical, Inc. is a biopharmaceutical company focused on the development of product candidates for disorders of the central nervous system (CNS). The Company has drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The Company also has a drug development program subject to regulatory review, Indiplon, which is being developed as a treatment for insomnia. The Company has sublicensing agreements for the development and commercialization of certain product candidates with XTL Biopharmaceuticals, Inc. (XTL) for bicifadine, with Blue Note Pharmaceuticals, Inc. (Blue Note) for DOV diltiazem, and with Neurocrine Biosciences, Inc. (Neurocrine) for indiplon.

Æterna Zentaris Inc. company was founded in 1991 and is headquartered in Quebec, Canada. Æterna Zentaris Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for endocrine therapy and oncology. Its lead product candidates in endocrinology are cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist that has completed Phase III trial for benign prostatic hyperplasia (BPH); and AEZS-130, an oral ghrelin antagonist in a Phase III trial as a diagnostic test for Growth Hormone Deficiency. Æterna Zentaris company's lead products in cancer are perifosine, a PI3K/Akt pathway inhibitor in Phase III for multiple myeloma, and AEZS-108, a Phase II clinical trial product for the treatment of advanced ovarian and endometrial cancers, as well as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma. Its pipeline also include compounds in pre clinical development, such as AEZS-115, an LHRH antagonist for endometriosis and urology; AEZS-120, an anti-cancer vaccine; AEZS-126 Erk and PI3K inhibitors for oncology; and AEZS-127 ErPC for oncology. Æterna Zentaris has partnership agreements with Shionogi and Co.; sanofi-aventis; Nippon Kayaku Co. Ltd.; Spectrum Pharmaceuticals, Inc.; Handok Pharmaceuticals Co., Ltd.; and Keryx Biopharmaceuticals, Inc.

CXR Biosciences Ltd. company was founded in 2001 and is based in Dundee, the United Kingdom. CXR Biosciences Ltd. provides drug development solutions and investigative toxicology services. Its drug development solutions include bioavailability, patient response variation, drug/drug interactions, drug reactions, toxicity, reactive metabolites, customized assay development, and anticancer drug development services. The company also offers mechanistic toxicology, collaborative research, and microarray services. In addition, it provides various preclinical screening systems that include Hepatic Reductase Null, which is used for determining the role of hepatic P450 metabolism in drug disposition; ToxReporter Mice for the mechanistic assessment of potential toxic effects in vivo; antioxidant response elements; ToxReporter cell lines for drug safety screening; and nuclear hormone receptor transactivation assays. Further, the company licenses its products.

Cypress Bioscience, Inc. was founded in 1981 and is based in San Diego, California. Cypress Bioscience, Inc. provides therapeutics and personalized medicine services. The company focuses on addressing the needs of physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders, such as fibromyalgia and rheumatoid arthritis. It offers Savella, a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine for the management of fibromyalgia. The company provides personalized medicine services, which include tests that are validated analytically and clinically to provide physicians with actionable information to help manage their patients care, including predicting the likelihood of developing disease or optimizing therapy. Its personalized medicine services include Avise PG, a test that supports dose optimization and therapeutic decision making for patients taking methotrexate, a therapy for rheumatoid arthritis (RA); and Avise MCV, a test that aids in the diagnosis and prognosis of RA. The company has a license agreement with Pierre Fabre Medicament to develop and sell products with the compound milnacipran as an active ingredient for various indications in the United States and Canada; a collaboration agreement with Forest Laboratories, Inc. for the development and marketing of milnacipran; and a reformulation and new product agreement with Collegium Pharmaceutical, Inc.

CorMedix believes the way to a healthy heart is through the kidney -- and vice versa. The biopharmaceutical company develops medications for the treatment and prevention of cardiorenal disease (kidney and related cardiac dysfunctions), including a liquid and gel used to prevent infection and clotting which can occur during intravenous treatments, such as dialysis and chemotherapy. Also, in an agreement with Shiva Biomedical, the company is developing a new formulation of the drug deferipone, to be used in the prevention of kidney damage in high-risk patients. The company expects to market its products worldwide. CorMedix, controlled by a group of its officers, filed to go public in November 2009.

Stallergenes is focused on the development, manufacture, and distribution of immunotherapeutic treatments for food-related and environmental allergies. The company has brought together experts from the fields of biology, botany, and the health community to collaborate on finding ways to deliver relief to people who suffer with problems ranging from asthma to seasonal allergies. These immunotherapy treatments involve conditioning the patient with drugs that introduce pure extracts of the allergen to initiate the body's own natural defenses against it. Wendel Investissement owns about 49% of the company. Stallergenes has research laboratories in Africa, the Americas, Asia, Australia, Europe, and the Middle East.

NeurogesX, Inc. (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates and is developing new therapies based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company’s most advanced product candidate, Qutenza, a dermal patch containing a high concentration of synthetic capsaicin, is designed to manage pain associated with peripheral neuropathic pain conditions. The Company submitted to the United States Food and Drug Administration’s (FDA) an new drug application (NDA) for Qutenza for the management of pain associated with postherpetic neuralgia (PHN), in October 2008 which was filed by the FDA in December 2008. The Company's Products include Qutenza, NGX-1998, Acetaminophen Prodrugs (NGX-1576, NGX-9674, NGX-5752) and Opioid Prodrugs (NGX-6052).

Sandoz International GmbH engages in the development, production, marketing, and distribution of generic medicines, pharmaceutical and biotechnological active substances, and anti-infectives in Germany and internationally. It offers products for various therapeutic areas, including cardiovascular system, central nervous system, gastrointestinal system, muscle and skeletal system, hormone therapy, and respiratory system. The company’s product portfolio ranges from various application forms, such as oral solids through technologies, including inhalers or injectables to transdermal patches, implants, and biopharmaceutical follow-ons. It sells its products to wholesalers, pharmacies, hospitals, and other healthcare outlets. Sandoz International GmbH was founded in 1886 and is headquartered in Holzkirchen, Germany. The company has research and development, and production sites in Boucherville, Canada; Buenos Aires, Argentina; Cambe and Taboao da Serra, Brazil; Holzkirchen/Rudolstadt and Barleben, Germany; Kolshet, Kalwe, and Mahad, India; Kundl and Schaftenau, Austria; Menges and Ljubljana, Slovenia; Wilson, North Carolina; Broomfield, Colorado; Gebze and Syntex, Turkey; and Strykow, Poland. Sandoz International GmbH operates as a subsidiary of Novartis AG.

Alexza Pharmaceuticals, Inc. was founded in 2000 and is based in Mountain View, California. Alexza Pharmaceuticals, Inc., a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that allows for systemic drug delivery. The company has six product candidates in clinical development, including AZ-004 (Staccato loxapine) that completed Phase 3 clinical trial for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-104 (Staccato loxapine), which completed Phase 2a clinical trial to treat patients suffering from acute migraine headaches; and AZ-001 (Staccato prochlorperazine) that completed Phase 2b clinical trials to treat patients suffering from acute migraine headaches.Alexza products in clinical development also include AZ-007 (Staccato zaleplon), which completed Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep; AZ-003 that completed Phase 1 clinical trial (Staccato fentanyl) for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes; and AZ-002 (Staccato alprazolam), which completed Phase 2a proof-of-concept clinical trial for the treatment of panic attacks. The company has a development agreement with Autoliv ASP, Inc. to develop heat packages to incorporate into the company's single dose drug delivery devices. It was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005.

Diosynth Biotechnology is all about the cGMP and protein. The company is a leading provider of cGMP (Current Good Manufacturing Practices) production for recombinant therapeutic proteins and peptides. Diosynth's line of proteins include monoclonal antibodies, cancer vaccines, fusion proteins, hormones, cancer vaccines, and anti-coagulants. The company also offers contract manufacturing, process development, and validation services. Diosynth has manufacturing facilities in the US, serving a wide range of customers. The company (which originally began operating in 1923) was a subsidiary of Akzo Nobel until Schering-Plough bought that company's pharmaceutical operations in 2007.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.